Pembrolizumab Plus Chemoradiotherapy Shows Statistically Significant PFS Benefit vs SOC in High-Risk Locally Advanced Cervical Cancer
The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival when compared with placebo plus EBRT/chemoradiotherapy/brachytherapy in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
United States Domenica Lorusso International Federation Of Gynecology Gynecologic Program Catholic University Of Rome University Of Arizona College Medicine
Source: onclive.com